|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Amortization of premium and accretion of discounts, net | |||||
| Amortization of operating lease right-of-use assets | |||||
| Amortization of debt discount | |||||
| Change in fair value of strategic investments | |||||
| Provision for credit losses and contractual allowances | |||||
| Acquired in-process research and development | |||||
| Loss on extinguishment of debt | |||||
| Impairment charges | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventory | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable and accrued liabilities | |||||
| Accrued liabilities | |||||
| Deferred revenue | |||||
| Operating lease liabilities | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of property and equipment | |||||
| Purchases of marketable securities | |||||
| Sales of marketable securities | |||||
| Maturities of marketable securities | |||||
| Purchases of strategic investments | |||||
| Purchase of acquired in-process research and development | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Payment of term loan/debt and termination costs | |||||
| SVB Term Loan | |||||
| Braidwell Term Loan Facility | |||||
| Total payment of term loan/debt and termination costs | |||||
| Proceeds from term loan/debt | |||||
| SVB Term Loan | |||||
| Braidwell Term Loan Facility | |||||
| Total proceeds from term loan/debt | |||||
| Payment of issuance costs for long-term debt | |||||
| Braidwell Term Loan Facility | |||||
| Convertible Notes Due 2029 | |||||
| Total payment of issuance costs for long-term debt | |||||
| Proceeds from issuance of 2029 notes | |||||
| Purchases of capped call transactions | |||||
| Purchase of treasury stock | |||||
| Proceeds from issuance of common stock in connection with employee equity incentive plans | |||||
| Tax withholding upon vesting of restricted stock awards | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate changes | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of year | |||||
| Cash and cash equivalents, end of year | |||||
| Supplemental disclosures of cash flow information: | |||||
| Interest paid | |||||
| Cash taxes paid | |||||
| Cash paid for operating lease liabilities | |||||
| Cash received from tenant improvement allowances | |||||
| Non-cash investing and financing activities: | |||||
| Property and equipment costs included in accounts payable and accrued liabilities | |||||
| Right-of-use assets obtained in exchange for operating lease liabilities | |||||
| Capitalized stock-based compensation in property and equipment | |||||
| Reconciliation of cash, cash equivalents and restricted cash | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...